Marinus Pharmaceuticals (NASDAQ:MRNS) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note released on Wednesday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

MRNS has been the subject of several other reports. Truist Financial cut Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $4.00 price objective on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $0.50 price objective (down from $5.00) on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. Oppenheimer raised Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price objective for the company in a research note on Monday, September 23rd. Finally, LADENBURG THALM/SH SH downgraded Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 14th. Nine research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Marinus Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $4.79.

Marinus Pharmaceuticals Price Performance

MRNS opened at $0.30 on Wednesday. The business has a 50 day simple moving average of $0.90 and a 200-day simple moving average of $1.21. The stock has a market capitalization of $16.81 million, a P/E ratio of -0.12 and a beta of 1.25. Marinus Pharmaceuticals has a 12 month low of $0.26 and a 12 month high of $11.26.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Several hedge funds have recently bought and sold shares of MRNS. Point72 DIFC Ltd purchased a new position in Marinus Pharmaceuticals during the second quarter worth $28,000. SG Americas Securities LLC purchased a new position in Marinus Pharmaceuticals during the second quarter worth $34,000. AQR Capital Management LLC increased its position in Marinus Pharmaceuticals by 70.3% during the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 12,934 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Marinus Pharmaceuticals during the second quarter worth $64,000. Finally, Values First Advisors Inc. increased its position in Marinus Pharmaceuticals by 501.8% during the second quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock worth $73,000 after buying an additional 52,257 shares in the last quarter. Hedge funds and other institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.